Table 3.
Characteristics of patients with changes in bone marrow of two or more grades on the modified Bauermeister scale
| Cohort | Age, years | Sex | Race | Prior splenectomy | Time with platelet response, % | Median (Q1, Q3) romiplostim dose, μg/kg | Total weeks on drug | Collagen | Cytopenia |
|---|---|---|---|---|---|---|---|---|---|
| 2 | 49 | M | White | N | 82 | 3 (3, 3) | 156a | ||
| 48 | F | White | Y | 0 | 7 (4, 10) | 13 | |||
| 3 | 81 | M | White | N | 0 | 9 (8, 9) | 156 | Anemia | |
| 30 | M | White | N | 0 | 10 (7, 10) | 26 | Present | ||
| 32 | F | White | N | 72 | 10 (7, 10) | 156 | |||
| 60 | M | White | Y | 5 | 10 (10, 10) | 156 | Present | ||
| 29 | F | White | N | 72 | 9 (5, 10) | 156 | Neutropenia | ||
| 47 | F | White | Y | 84 | 9 (9, 9) | 156 | |||
| 53 | F | White | N | 0 | 5 (2, 7) | 9 | Anemia |
Cytopenias were defined as Common Terminology Criteria for Adverse Events grade 2 or greater shift in white blood cell (neutropenia) or red blood cell (anemia) adverse events or laboratory values
F female, M male, N no, Q1 quartile 1, Q3 quartile 3, Y yes
aAs patients were allowed to remain on romiplostim for 3 years (i.e., even after biopsy for patients in cohorts 1 and 2), this patient had the option of continuing treatment, which he did for another 52 weeks after biopsy at week 104